Idiotypic protein‐pulsed dendritic cell vaccination in multiple myeloma
Explore this paper's citation graph
Summary
Idiotypic protein (Id) produced by myeloma cells is clone‐specific and may be a suitable tumor‐specific antigen for immune targeting and Id‐pulsed DC vaccination can elicit potentially useful anti‐myeloma immune responses in patients with multipleMyeloma.
- Type
- article
- Published
- 1999-10-08
- Cited by
- 173
- References
- 21
- Access
- Open access
- OpenAlex
- https://openalex.org/W2021488008
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25314895
Keywords
Immune system, Dendritic cell, Antigen, Immunology, Medicine
References
- The phenotype of freshly isolated and cultured human bone marrow allostimulatory cells: possible heterogeneity in bone marrow dendritic cell populations.
- Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
- Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells.
- Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma.
- Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
- Idiotypic vaccination as a treatment for a B cell lymphoma.
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
- Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function
- GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
- Immunogenicity and cross‐reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma
- Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
- Idiotype‐specific T cells in multiple myeloma stage I: an evaluation by four different functional tests
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
- T cells recognize the VH complementarity‐determining region 3 of the idiotypic protein of B cell non‐Hodgkin's lymphoma
- Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
- Cytokine enhancement of immunogenicity in chronic myeloid leukaemia
- Proliferating dendritic cell progenitors in human blood
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
- Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Cited by
- Antitumor activities of human dendritic cells derived from peripheral and cord blood.
- Monocyte-derived Dendritic Cells in Chronic Lymphocytic Leukemia
- Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell‐based immunotherapy
- Dendritic cell-based vaccines for cancer therapy.
- Cellular immunotherapy of cancer: an overview and future directions.
- Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived DC for immune therapy.
- Active Immunization of Humans with Dendritic Cells
- Dendritic cell-based immunotherapy.
- Dendritic cells and antigen trapping technology--a revolution in vaccine/immunotherapy strategy.
- Immunology and immunotherapeutic approaches in multiple myeloma.
- Dendritic Cells and Virus Infection
- Immunological and Clinical Long-Term Effects of Idiotype Vaccination in Multiple Myeloma Patients
- A review of the cytokine network in multiple myeloma
- Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.
- Clinical results of vaccine therapy for cancer: learning from history for improving the future.
- Tumour‐associated antigens in multiple myeloma
- Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma1
- Tumor vaccine: current trends in antigen specific immunotherapy.
- Current issues in dendritic cell cancer immunotherapy.
- Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
Related papers
- Dendritic cell-based glioma immunotherapy (review).
- Dendritic cell vaccines.
- Use of interferon-α-induced dendritic cells in the therapy of patients with malignant brain gliomas
- Current issues in antigen presentation--focus on the dendritic cell.
- [Dendritic cell therapy for malignant glioma].
- Dendritic-cell- and peptide-based vaccination strategies for glioma
- The relationship on dendritic cells and HIV-1 immunotherapy
- Antigen processing and autophagy function in adjuvant treated dendritic cell
- Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.